Pinnacle Technology, Inc. — Department of Defense STTR Phase II: ST12A-003
Pinnacle Technology, Inc. — STTR Phase II award from Department of Defense.
Phase II STTR prototype / development signal
- Phase II is where Department of Defense funds deeper R&D after feasibility. Incumbents with Phase II history are serious competitors on adjacent topics.
- Use this award as past-performance context and to map customer organizations for STRATFI/TACFI-style transition planning.
- Obligated amount $723,765 is consistent with substantial Phase II-scale effort; compare to related awards from the same agency.
- Topic code ST12A-003 links this award to a solicitation family — search the same topic stem for incumbents and recompete timing.
- Amount
- $723,765
- Agency
- Department of Defense · Defense Advanced Research Projects Agency
- Program / Phase
- STTR · Phase II
- Topic
- ST12A-003
- Solicitation
- 2012.0
- NAICS
- —
- Place of performance
- KS
- Period
- 2013-11-05 → 2016-02-06
Description
Point of care (POC) diagnostic devices are a well established market but have significant growth opportunities. Stable off-the-shelf biological recognition elements available in a form that can be readily incorporated into POC devices will be essential for wide spread use and deployment. Other than glucose oxidase, stable active oxidase enzymes are not available. Pinnacle has developed intellectual property (patent PCT/US11/51193) that provides a general solution for the use of cofactors to maximize the activity of oxidase enzymes used in diagnostic devices. We have also discovered that fusion proteins can dramatically enhance the stability of oxidases without compromising catalytic activity. Using high throughput screening of fusion proteins, directed evolution and large scale protein production in E.coli, we are developing a platform methodology for the optimization of existing (e.g. histamine, lactate), and the creation of new (e.g.cortisol) oxidases. Pinnacle Technology manufactures, sells and warranties biosensors for the detection of glucose, glutamate, lactate, and alcohol in animals. With the Richter and Gao laboratories at the University of Kansas, we have successfully cloned, expressed, purified and characterized oxidases for biosensors. The enzymes produced will be available for direct sale, or as biosensors. World-wide total biosensor sales are expected to reach $14 billion by 2016.